340B Update: HRSA Notifies Six Manufacturers That They Are In Violation Of The 340B Statute | Husch Blackwell LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to new data presented at the American College of Cardiology s 70th Annual Scientific Session.
A program designed to improve hospital care for patients with heart failure, the leading cause of hospitalization among adults over age 65, did not bring additional benefits beyond existing hospital quality improvement programs in a randomized controlled trial presented at the American College of Cardiology s 70th Annual Scientific Session.
Advances in the Care of Patients with Heart Failure: Reducing Hospital Readmission Rates
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation. 0.75 CME Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
CHICAGO | May 3, 2021
In April of 2020, in response to the urgent threat caused by the COVID-19 pandemic, the American Lung Association launched the COVID-19 Action Initiative, a three-year initiative to end COVID-19 and prevent future respiratory viruses with pandemic potential. The funds raised to support the COVID-19 Action Initiative enabled the organization to swiftly respond to the challenges posed by the pandemic through investments in critical research, education and advocacy efforts.
Since launching the COVID-19 Action Initiative, the Lung Association has invested in promising COVID-19 research projects, including 12 COVID-19 and Emerging Respiratory Viruses Awards. These commitments included expanding COVID-19 research within the current studies of the Airways Clinical Research Centers (ACRC) Network, examining the efficacy of the COVID-19 vaccine for transplant recipients, and the molecular analysis of antibody responses to reducing the spread of COVID-19